Menu
Recruiting NCT07268196

Impact of Liver Transplantation on Sexual Life and Function

Observational Chronic Liver Disease and Cirrhosis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: No Treatment.
Who it may be relevant to
Registry conditions: Chronic Liver Disease and Cirrhosis. Basic parameters: 18 years — 60 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
India
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Liver Transplantation (LT) is a lifesaving intervention with around 90% of recipients currently surviving the first postoperative year and subsequent life expectancy now exceeding 20 years. After the post-operative recovery period, however, LT recipients become more and more confronted with the challenges of re-engagement with life after transplantation, a need to reach a new stability, reestablish function in everyday life, reconnect with valued roles, regain independence, and resume work Sexual function is a very important parameter in the evaluation of Quality of Life (QoL), as it has been shown that sexual dysfunction in transplant patients is associated with increased depression and decreased QoL. There are several studies in the relevant literature supporting the recovery of sexual function in patients after liver transplantation. It has been found that recovery was observed in erectile dysfunction in male patients 6 months after liver transplantation.

Detailed description

Liver Transplantation (LT) is a lifesaving intervention with around 90% of recipients currently surviving the first postoperative year and subsequent life expectancy now exceeding 20 years. After the post-operative recovery period, however, LT recipients become more and more confronted with the challenges of re-engagement with life after transplantation, a need to reach a new stability, reestablish function in everyday life, reconnect with valued roles, regain independence, and resume work Sexual function is a very important parameter in the evaluation of Quality of Life (QoL), as it has been shown that sexual dysfunction in transplant patients is associated with increased depression and decreased QoL. There are several studies in the relevant literature supporting the recovery of sexual function in patients after liver transplantation. It has been found that recovery was observed in erectile dysfunction in male patients 6 months after LT

Interventions

  • Other No Treatment
    This is an Observational Study

Primary outcome measures

  • Evaluation of sexual function by questionnaire method [Time frame: pre transplant, 3,6,12 months]
  • Evaluation of erectile dysfunction using questionnaire method [Time frame: pre transplant, 3,6,12 months]
Secondary outcome measures (2)
  • Correlation between testosterone and Meld Na scores [Time frame: pre transplant, 3,6,12 months]
  • Sarcopenia implication in recovery of sexual function. [Time frame: pre transplant, 3,6,12 months]

Eligibility criteria

Inclusion criteria

  • Married male Patients.
  • Decompensated Chronic Liver Disease awaiting elective liver transplantation.
  • Post Liver Transplant patients with stable graft function.

Exclusion criteria

  • Negative consent.
  • Patients with ongoing medical and surgical issues (biliary complications, graft complication etc.).
  • Acute on Chronic Liver Failure and Acute Liver Failure patients.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

India · 1 center
  • ILBS — New Delhi

Identifiers

NCT: NCT07268196 · IEC/2024/110/MA03

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗